R. Burgess

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

M. Socinski, L. Tye, S. Novello, 2010, British Journal of Cancer.

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

M. Socinski, G. Scagliotti, R. Govindan, 2009, British Journal of Cancer.

Epilepsy with Eyelid myoclonias − A diagnosis concealed in other genetic generalized epilepsies with photoparoxysmal response

P. Kotagal, E. Wyllie, Deepak Lachhwani, 2022, Epilepsy Research.

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

K. Y. Wong, Mohammad A. Qayum, John S. Clouston, 2022, Lancet.

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

K. Y. Wong, Beverley E. Crane, Scott M Elliott, 2021, Lancet.